Epithelial Sodium Channel Inhibition by Amiloride on Blood Pressure and Cardiovascular Disease Risk in Young Prehypertensives

Jigar Bhagatwala, Ryan A. Harris, Samip J. Parikh, Haidong Zhu, Ying Huang, Ishita Kotak, Nichole Seigler, Gary L. Pierce, Brent M. Egan, Yanbin Dong

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Overactivity of the epithelial sodium channel (ENaC) is considered to be one mechanism underlying obesity-related blood pressure (BP) elevation. In an open-labeled, nonplacebo-controlled clinical trial (Clinicaltrials.gov: NCT-01308983), the authors aimed to comprehensively evaluate the effects of amiloride monotherapy, an ENaC blocker, on BP and cardiovascular risk in young adults with prehypertension (n=17). The mean body mass index of participants was 28.45±1.30 kg/m2. Following 10 mg daily amiloride for 4 weeks, peripheral systolic BP (SBP), central SBP, and carotid-radial pulse wave velocity were significantly reduced by -7.06±2.25 mm Hg, -7.68±2.56 mm Hg, and -0.72±0.33 m/s, respectively, whereas flow-mediated dilation was significantly increased by 2.2±0.9%. Following amiloride monotherapy for 4 weeks, a significant increase in serum aldosterone was observed (5.85±2.45 ng/dL). ENaC inhibition by amiloride may be used as an early intervention to halt the progression to full hypertension and cardiovascular disease in young adults with prehypertension.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalJournal of Clinical Hypertension
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Epithelial Sodium Channels
Hematologic Diseases
Amiloride
Cardiovascular Diseases
Prehypertension
Blood Pressure
Young Adult
Pulse Wave Analysis
Controlled Clinical Trials
Aldosterone
Dilatation
Body Mass Index
Obesity
Hypertension
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Epithelial Sodium Channel Inhibition by Amiloride on Blood Pressure and Cardiovascular Disease Risk in Young Prehypertensives. / Bhagatwala, Jigar; Harris, Ryan A.; Parikh, Samip J.; Zhu, Haidong; Huang, Ying; Kotak, Ishita; Seigler, Nichole; Pierce, Gary L.; Egan, Brent M.; Dong, Yanbin.

In: Journal of Clinical Hypertension, Vol. 16, No. 1, 01.01.2014, p. 47-53.

Research output: Contribution to journalArticle

Bhagatwala, Jigar ; Harris, Ryan A. ; Parikh, Samip J. ; Zhu, Haidong ; Huang, Ying ; Kotak, Ishita ; Seigler, Nichole ; Pierce, Gary L. ; Egan, Brent M. ; Dong, Yanbin. / Epithelial Sodium Channel Inhibition by Amiloride on Blood Pressure and Cardiovascular Disease Risk in Young Prehypertensives. In: Journal of Clinical Hypertension. 2014 ; Vol. 16, No. 1. pp. 47-53.
@article{1adcfbd2dc534d7abaf66b29d7504a24,
title = "Epithelial Sodium Channel Inhibition by Amiloride on Blood Pressure and Cardiovascular Disease Risk in Young Prehypertensives",
abstract = "Overactivity of the epithelial sodium channel (ENaC) is considered to be one mechanism underlying obesity-related blood pressure (BP) elevation. In an open-labeled, nonplacebo-controlled clinical trial (Clinicaltrials.gov: NCT-01308983), the authors aimed to comprehensively evaluate the effects of amiloride monotherapy, an ENaC blocker, on BP and cardiovascular risk in young adults with prehypertension (n=17). The mean body mass index of participants was 28.45±1.30 kg/m2. Following 10 mg daily amiloride for 4 weeks, peripheral systolic BP (SBP), central SBP, and carotid-radial pulse wave velocity were significantly reduced by -7.06±2.25 mm Hg, -7.68±2.56 mm Hg, and -0.72±0.33 m/s, respectively, whereas flow-mediated dilation was significantly increased by 2.2±0.9{\%}. Following amiloride monotherapy for 4 weeks, a significant increase in serum aldosterone was observed (5.85±2.45 ng/dL). ENaC inhibition by amiloride may be used as an early intervention to halt the progression to full hypertension and cardiovascular disease in young adults with prehypertension.",
author = "Jigar Bhagatwala and Harris, {Ryan A.} and Parikh, {Samip J.} and Haidong Zhu and Ying Huang and Ishita Kotak and Nichole Seigler and Pierce, {Gary L.} and Egan, {Brent M.} and Yanbin Dong",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/jch.12218",
language = "English (US)",
volume = "16",
pages = "47--53",
journal = "Journal of the CardioMetabolic Syndrome",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Epithelial Sodium Channel Inhibition by Amiloride on Blood Pressure and Cardiovascular Disease Risk in Young Prehypertensives

AU - Bhagatwala, Jigar

AU - Harris, Ryan A.

AU - Parikh, Samip J.

AU - Zhu, Haidong

AU - Huang, Ying

AU - Kotak, Ishita

AU - Seigler, Nichole

AU - Pierce, Gary L.

AU - Egan, Brent M.

AU - Dong, Yanbin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Overactivity of the epithelial sodium channel (ENaC) is considered to be one mechanism underlying obesity-related blood pressure (BP) elevation. In an open-labeled, nonplacebo-controlled clinical trial (Clinicaltrials.gov: NCT-01308983), the authors aimed to comprehensively evaluate the effects of amiloride monotherapy, an ENaC blocker, on BP and cardiovascular risk in young adults with prehypertension (n=17). The mean body mass index of participants was 28.45±1.30 kg/m2. Following 10 mg daily amiloride for 4 weeks, peripheral systolic BP (SBP), central SBP, and carotid-radial pulse wave velocity were significantly reduced by -7.06±2.25 mm Hg, -7.68±2.56 mm Hg, and -0.72±0.33 m/s, respectively, whereas flow-mediated dilation was significantly increased by 2.2±0.9%. Following amiloride monotherapy for 4 weeks, a significant increase in serum aldosterone was observed (5.85±2.45 ng/dL). ENaC inhibition by amiloride may be used as an early intervention to halt the progression to full hypertension and cardiovascular disease in young adults with prehypertension.

AB - Overactivity of the epithelial sodium channel (ENaC) is considered to be one mechanism underlying obesity-related blood pressure (BP) elevation. In an open-labeled, nonplacebo-controlled clinical trial (Clinicaltrials.gov: NCT-01308983), the authors aimed to comprehensively evaluate the effects of amiloride monotherapy, an ENaC blocker, on BP and cardiovascular risk in young adults with prehypertension (n=17). The mean body mass index of participants was 28.45±1.30 kg/m2. Following 10 mg daily amiloride for 4 weeks, peripheral systolic BP (SBP), central SBP, and carotid-radial pulse wave velocity were significantly reduced by -7.06±2.25 mm Hg, -7.68±2.56 mm Hg, and -0.72±0.33 m/s, respectively, whereas flow-mediated dilation was significantly increased by 2.2±0.9%. Following amiloride monotherapy for 4 weeks, a significant increase in serum aldosterone was observed (5.85±2.45 ng/dL). ENaC inhibition by amiloride may be used as an early intervention to halt the progression to full hypertension and cardiovascular disease in young adults with prehypertension.

UR - http://www.scopus.com/inward/record.url?scp=84892368049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892368049&partnerID=8YFLogxK

U2 - 10.1111/jch.12218

DO - 10.1111/jch.12218

M3 - Article

C2 - 24410943

AN - SCOPUS:84892368049

VL - 16

SP - 47

EP - 53

JO - Journal of the CardioMetabolic Syndrome

JF - Journal of the CardioMetabolic Syndrome

SN - 1524-6175

IS - 1

ER -